Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Common Equity (2020 - 2025)

Cytek Biosciences' Common Equity history spans 6 years, with the latest figure at $341.7 million for Q4 2025.

  • For Q4 2025, Common Equity fell 13.64% year-over-year to $341.7 million; the TTM value through Dec 2025 reached $341.7 million, down 13.64%, while the annual FY2025 figure was $341.7 million, 13.64% down from the prior year.
  • Common Equity reached $341.7 million in Q4 2025 per CTKB's latest filing, down from $378.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $425.5 million in Q4 2022 to a low of -$11.0 million in Q2 2021.
  • Average Common Equity over 5 years is $357.8 million, with a median of $394.4 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 36940.18% in 2022, then decreased 13.64% in 2025.
  • A 5-year view of Common Equity shows it stood at $405.4 million in 2021, then grew by 4.97% to $425.5 million in 2022, then dropped by 7.63% to $393.1 million in 2023, then rose by 0.68% to $395.7 million in 2024, then fell by 13.64% to $341.7 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Common Equity are $341.7 million (Q4 2025), $378.6 million (Q3 2025), and $377.6 million (Q2 2025).